[go: up one dir, main page]

MXPA04006181A - Polvo farmaceutico o nutraceutico micronizado, con liberacion inmediata. - Google Patents

Polvo farmaceutico o nutraceutico micronizado, con liberacion inmediata.

Info

Publication number
MXPA04006181A
MXPA04006181A MXPA04006181A MXPA04006181A MXPA04006181A MX PA04006181 A MXPA04006181 A MX PA04006181A MX PA04006181 A MXPA04006181 A MX PA04006181A MX PA04006181 A MXPA04006181 A MX PA04006181A MX PA04006181 A MXPA04006181 A MX PA04006181A
Authority
MX
Mexico
Prior art keywords
immediate release
micronized pharmaceutical
nutraceutical powder
nutraceutical
powder
Prior art date
Application number
MXPA04006181A
Other languages
English (en)
Inventor
Besse Jerome
Original Assignee
Besins Int Belgique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Besins Int Belgique filed Critical Besins Int Belgique
Publication of MXPA04006181A publication Critical patent/MXPA04006181A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La invencion se refiere a un polvo farmaceutico o nutraceutico, micronizado, con liberacion inmediata y que tiene una distribucion del tamano de grano de no mas que 100 mum, y que consiste en la combinacion de al menos una sustancia activa, al menos un agente humectante y al menos un diluyente.
MXPA04006181A 2001-12-27 2002-12-27 Polvo farmaceutico o nutraceutico micronizado, con liberacion inmediata. MXPA04006181A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0116934A FR2834212B1 (fr) 2001-12-27 2001-12-27 Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
PCT/FR2002/004575 WO2003055464A1 (fr) 2001-12-27 2002-12-27 Poudre micronisee pharmaceutique ou nutraceutique a liberation immediate.

Publications (1)

Publication Number Publication Date
MXPA04006181A true MXPA04006181A (es) 2005-04-19

Family

ID=8871027

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04006181A MXPA04006181A (es) 2001-12-27 2002-12-27 Polvo farmaceutico o nutraceutico micronizado, con liberacion inmediata.

Country Status (14)

Country Link
US (2) US20030124191A1 (es)
EP (1) EP1458356A1 (es)
JP (1) JP2005520799A (es)
AU (1) AU2002364489A1 (es)
BR (1) BR0215380A (es)
CA (1) CA2471903A1 (es)
FR (1) FR2834212B1 (es)
HU (1) HUP0500509A3 (es)
IL (1) IL162671A0 (es)
MX (1) MXPA04006181A (es)
NO (1) NO20043172L (es)
PL (1) PL370202A1 (es)
RU (1) RU2302232C2 (es)
WO (1) WO2003055464A1 (es)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6974590B2 (en) * 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
NZ518447A (en) 1999-10-29 2004-10-29 Orion Corp Treatment or prevention of hypotension and shock
IL150294A0 (en) 1999-12-28 2002-12-01 Ajinomoto Kk Antidiabetic preparation for oral administration
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
SE521512C2 (sv) 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
US6830759B2 (en) * 2002-06-28 2004-12-14 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration
CA2511185C (en) 2002-12-20 2012-09-18 Niconovum Ab A physically and chemically stable nicotine-containing particulate material
WO2004073729A1 (ja) 2003-02-21 2004-09-02 Translational Research Ltd. 薬物の経鼻投与用組成物
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
JP2005097221A (ja) * 2003-09-26 2005-04-14 Sato Pharmaceutical Co Ltd 点鼻薬
US8987322B2 (en) * 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
EP1547592A1 (en) * 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
KR101184138B1 (ko) * 2003-12-31 2012-09-19 시마 랩스 인크. 일반적인 선형 발포성 경구 펜타닐 투약 제형 및 투여 방법
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US9114069B2 (en) 2004-08-25 2015-08-25 Aegis Therapeutics, Llc Antibacterial compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
RS20070166A (sr) 2004-10-20 2008-09-29 Endorecherche Inc., Prekursori seksualnih steroida sami ili u kombinaciji sa selektivnim modulatorom estrogenskog receptora i/ili sa inhibitorom cgmp fosfodiesteraze tipa 5 za prevenciju ili tretman isušenosti vaginalne sluzokože i seksualne disfunkcije kod žena u postmenopauzi
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
DE102005042875A1 (de) * 2004-12-23 2006-09-21 Grünenthal GmbH Schnell freisetzende Darreichungsformen für Antibiotika
RU2370268C2 (ru) * 2005-05-25 2009-10-20 Лабораториос Баго С.А. Способ получения фармацевтической композиции для орального введения, обладающей улучшенной биодоступностью биологически активного действующего лекарственного вещества, и фармацевтическая композиция, полученная этим способом
US20060281775A1 (en) * 2005-06-14 2006-12-14 Applied Pharmacy Services, Inc. Two-component pharmaceutical composition for the treatment of pain
EP1983998A2 (en) * 2006-01-20 2008-10-29 Pear Tree Pharmaceuticals, Inc. Method of treating atrophic vaginitis
WO2007104573A2 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
KR20150050595A (ko) * 2006-03-28 2015-05-08 자블린 파머슈티칼스 인코포레이티드 저 복용량의 디클로페낙 및 베타-사이클로덱스트린 제형
CA2647533A1 (en) * 2006-03-28 2007-10-04 Javelin Pharmaceuticals, Inc. Formulations of low dose non-steroidal anti-inflammatory drugs and beta-cyclodextrin
US9693953B2 (en) * 2006-06-02 2017-07-04 Janet A. Chollet Method of treating atrophic vaginitis
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
ES2478633T3 (es) * 2006-09-13 2014-07-22 22Nd Century Limited, Llc Aumento de los niveles de alcaloides nicotínicos
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
CN101668544B (zh) * 2006-12-26 2013-04-24 株式会社新日本科学 经鼻投用制剂
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
AU2008261957A1 (en) 2007-06-08 2008-12-18 Addrenex Pharmaceuticals, Inc. Extended release formulation and method of treating adrenergic dysregulation
US20100172991A1 (en) * 2007-06-08 2010-07-08 Henry Joseph Horacek Extended Release Formulation and Methods of Treating Adrenergic Dysregulation
US8268806B2 (en) * 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
EP2207533B1 (en) * 2007-10-10 2021-01-06 Avantor Performance Materials, LLC Directly compressible high functionality granular microcrystalline cellulose based excipient, manufacturing process and use thereof
US20100055180A1 (en) * 2007-10-10 2010-03-04 Mallinckrodt Baker, Inc. Directly Compressible Granular Microcrystalline Cellulose Based Excipient, Manufacturing Process and Use Thereof
CN101938995A (zh) * 2007-12-17 2011-01-05 克卡制药新梅斯托股份公司 包含非微粉化依泽替米贝微粒的悬浮液
RU2372073C1 (ru) * 2008-02-27 2009-11-10 Николай Лазаревич Векшин Доставка гетероциклических антибиотиков к раковым клеткам с помощью нанонуклеотидных фармакосом
US20090246273A1 (en) * 2008-03-27 2009-10-01 Al-Ghananeem Abeer M Ketorolac Sublingual Spray for the Treatment of Pain
EP2271347B1 (en) 2008-03-28 2016-05-11 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
US20100022471A1 (en) * 2008-07-23 2010-01-28 Sage Products Inc. Oral Moisturizer for Alleviating Dry Mouth
RU2457857C2 (ru) * 2008-08-05 2012-08-10 Виктор Владимирович Чалов Противовирусная и антимикробная композиция
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
US9101539B2 (en) 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
KR101859486B1 (ko) * 2009-05-15 2018-06-28 레크로파마, 인코포레이티드 설하용 덱스메데토미딘 조성물과 그의 사용 방법
PL2515874T3 (pl) * 2009-12-22 2015-01-30 Leo Pharma As Nanokryształy jednowodnego kalcypotriolu
AU2012204462A1 (en) 2011-01-05 2013-07-11 Hospira, Inc. Spray drying vancomycin
CN103796656A (zh) 2011-06-14 2014-05-14 哈尔生物药投资有限责任公司 苯二氮卓的投与
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
SG11201403094TA (en) 2011-12-11 2014-10-30 Recro Pharma Inc Intranasal dexmedetomidine compositions and methods of use thereof
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
JP2016531850A (ja) * 2013-09-24 2016-10-13 株式会社新日本科学 頭痛治療用の鼻腔内ｄｈｅ
US8785426B1 (en) 2013-12-13 2014-07-22 Upsher-Smith Laboratories, Inc. Testosterone gel compositions and related methods
CN104042562A (zh) * 2014-05-21 2014-09-17 丽珠医药集团股份有限公司 一种罗红霉素的新固体制剂
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
KR101729236B1 (ko) * 2015-06-01 2017-04-21 (주)노터스생명과학 Tlr7 항진제를 포함하는 비만 또는 간질환 예방 및 치료용 약학 조성물
MX382254B (es) * 2015-06-30 2025-03-13 Hanmi Pharmaceutical Co Ltd Formulacion farmaceutica de complejo que comprende amlodipino, losartan y rosuvastatina.
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
MX2018011705A (es) 2016-04-01 2019-06-10 Therapeuticsmd Inc Composicion farmaceutica de hormona esteroide.
JP7297308B2 (ja) 2016-08-19 2023-06-26 オラシス ファーマシューティカルズ リミティド 眼科用医薬組成物及びそれに関する使用
ES2980126T3 (es) 2016-12-31 2024-09-30 Bioxcel Therapeutics Inc Uso de dexmedetomidina para el tratamiento de la agitación
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
BR112020013750A8 (pt) 2018-01-05 2022-10-18 Impel Neuropharma Inc Dispensação intranasal de olanzapina por dispositivo olfativo de precisão
WO2020006092A1 (en) 2018-06-27 2020-01-02 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
CN109125733A (zh) * 2018-10-30 2019-01-04 成都先手生物科技有限公司 一种治疗关节炎的组合物及其应用
US10758532B2 (en) 2018-12-11 2020-09-01 Satsuma Pharmaceuticals, Inc. Compositions, devices, and methods for treating or preventing headaches
WO2021016112A2 (en) 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
US12171872B2 (en) 2019-12-09 2024-12-24 Nicoventures Trading Limited Oral compositions and methods of manufacture
JP2023505351A (ja) 2019-12-09 2023-02-08 ニコベンチャーズ トレーディング リミテッド 口腔用組成物のための薬剤
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
ES2929818T3 (es) 2020-05-18 2022-12-02 Orexo Ab Nueva composición farmacéutica para la administración de fármacos
IL313016A (en) 2021-11-25 2024-07-01 Orexo Ab A pharmaceutical preparation that includes adrenaline
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
JP2025536556A (ja) 2022-10-25 2025-11-07 ヴェラダーミクス インコーポレイテッド 放出調節ミノキシジル用組成物および使用方法
CN115501236B (zh) * 2022-11-09 2024-01-23 复旦大学附属肿瘤医院 一种醋酸烯诺孕酮在制备降低肺部炎症性疾病的药物中的应用
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
WO2025196244A1 (en) 2024-03-22 2025-09-25 Helm Pharmaceuticals Gmbh Particulate formulation of 5-amino levulinic acid for oral administration

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4760093A (en) * 1986-10-21 1988-07-26 American Home Products Corporation (Del.) Spray dried acetaminophen
JPH01213245A (ja) * 1988-02-20 1989-08-28 Ueno Seiyaku Oyo Kenkyusho:Kk 固体状ソルビトールの製法
DE3827362A1 (de) * 1988-08-12 1990-02-15 Basf Ag Pulvrige, hydrophile theophyllinformulierung und verfahren zur ihrer herstellung
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
US5157030A (en) * 1989-08-25 1992-10-20 Alexander Galat Rapidly soluble aspirin compositions and method
EP0587744B1 (en) * 1991-05-28 2003-07-16 McNEIL-PPC, Inc. Chewable drug-delivery composition
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
AU1307399A (en) * 1997-11-06 1999-05-31 Orbon Corporation Stabilized, dry pharmaceutical compositions for drug delivery and methods of preparing same
UA72207C2 (uk) * 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
BR0010349B1 (pt) * 1999-05-07 2011-10-04 derivados de ácido propanóico que inibem a ligação de integrinas aos seus receptores.
FR2795962B1 (fr) * 1999-07-08 2003-05-09 Prographarm Laboratoires Procede de fabrication de granules enrobes a gout masque et liberation immediate du principe actif
WO2001046040A1 (en) * 1999-12-20 2001-06-28 Merck & Co., Inc. Blister package for pharmaceutical treatment card

Also Published As

Publication number Publication date
CA2471903A1 (fr) 2003-07-10
BR0215380A (pt) 2004-12-07
PL370202A1 (en) 2005-05-16
HUP0500509A3 (en) 2012-07-30
US20050118272A1 (en) 2005-06-02
HUP0500509A2 (hu) 2005-09-28
EP1458356A1 (fr) 2004-09-22
NO20043172L (no) 2004-09-14
IL162671A0 (en) 2005-11-20
FR2834212B1 (fr) 2004-07-09
RU2004122919A (ru) 2005-04-10
RU2302232C2 (ru) 2007-07-10
JP2005520799A (ja) 2005-07-14
FR2834212A1 (fr) 2003-07-04
AU2002364489A1 (en) 2003-07-15
US20030124191A1 (en) 2003-07-03
WO2003055464A1 (fr) 2003-07-10

Similar Documents

Publication Publication Date Title
MXPA04006181A (es) Polvo farmaceutico o nutraceutico micronizado, con liberacion inmediata.
MXPA04004791A (es) Polvo micronizado para la formacion de peliculas que comprenden una sustancia activa.
IL159086A0 (en) 3-aryl-5-aryl- [1, 2, 4] -oxadiazole derivatives and pharmaceutical compositions containing the same
IL161587A0 (en) Pharmaceutical containing 3 (3-dimethylamino-1-ethyl-2-methyl-propyl) phenol and providing delayed release of the active ingredient
IL159022A0 (en) Hv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
HUP0303148A3 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, pharmaceutical compositions containing the compounds and processes for their preparation
AU1095202A (en) Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist
IL163552A (en) Conjugates of biologically active compounds, uses thereof and pharmaceutical compositions comprising the same
CA2326756A1 (en) Pharmaceutical compositions containing compounds with activity for the enhancement of absorption of active ingredients
EP1476138A4 (en) MODIFIED RELEASE FORMULATIONS OF AT LEAST ONE TRAMADOL FORM
IL161857A0 (en) Pharmaceutical compositions of 5,7,14-triazatetracycloÄ10.3.1.0(2,11).0(4,9)Ü-hexadeca-2(11)3,5,7,9-pentaene
IL133397A (en) Pharmaceutical compositions for oral administration comprising an active substance and a cyclodextrin
IL140897A0 (en) Benzocycloheptene derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
HUP0401638A3 (en) Thiopene-amides, thiazolesulfonamides as antineoplastic agents, and pharmaceutical composition containing the same
IL158671A0 (en) Benzyloxy derivatives and pharmaceutical compositions containing the same
HUP0400179A3 (en) 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines, their use and pharmaceutical compositions containing them
MXPA03008420A (es) Forma farmaceutica solida oralmente dispersa.
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
WO2003035686A3 (en) Compositions of fsh with high sialylation degree and their use for the preparation of medicaments
HUP0402028A3 (en) Unsaturated 1-amino-alkylcyclohexane derivatives, pharmaceutical compositions containing them and use thereof
HUP0303155A3 (en) 2-thio-substituted imidazole derivatives, the use thereof and pharmaceutical compositions containing them
EP1607097A3 (en) Stabilized compositions containing an oxygen-labile agent
GB2363571A (en) Brassica extracts or sulforaphane in combination with reseratol as antitumor agents
WO2006023814A3 (en) Effervescent composition including a grape-derived component
BG105303A (en) Pharmaceutical compositions comprising ibuprofen and domperidone

Legal Events

Date Code Title Description
FA Abandonment or withdrawal